Diabetes Patients Need Better Drug Coverage

Bill C‑64, introduced on February 29, 2024, marks Canada’s first step toward a national pharmacare program that explicitly includes diabetes medications and a device fund in its initial phase. With more than four million Canadians living with diabetes, the announcement raised hopes that cost barriers to essential treatments might finally be lowered.

What the proposal currently covers

The federal plan outlines a list of drugs that will be reimbursed under a single‑payer system. Critics say the list leans heavily toward older, lower‑priced medicines, leaving out many of the newer, guideline‑recommended treatments that Diabetes Canada cites in its clinical practice recommendations. Those recommendations are based on extensive reviews of published research, grading each drug’s relevance and quality.

Because the public formulary will be the sole source of coverage for those without private insurance, patients could face a choice between their doctor’s preferred prescription and the drugs the plan actually funds. The concern is that this mismatch may create a two‑tier system where only those who can afford out‑of‑pocket costs receive the most effective therapies.

Potential impact on existing private coverage

Some Canadians already have diabetes drugs covered through employer benefits or private insurers. Those plans are beginning to drop coverage for certain medications, assuming the public plan will pick up the slack. The shift could unintentionally strip patients of the drugs they have been using, especially if the public list does not include those same products.

Under a single‑payer design, the public plan’s drug list would be the only one recognized for reimbursement. While the approach simplifies administration, it also risks overriding existing private arrangements, potentially leaving some patients without any coverage for the medicines they need.

There is still an opportunity to adjust the framework before it solidifies. Policymakers could move toward a multi‑payer model that allows both public and private plans to coexist, preserving patient choice while expanding access. Such a structure would aim to protect current coverage, close gaps in the formulary, and ensure equitable treatment for uninsured and underinsured individuals.

In practice, this would mean expanding the covered list to include all drugs endorsed by Diabetes Canada’s guidelines, guaranteeing that people who already have coverage do not lose access, and setting up a process for regular updates as new treatments are available. Engaging patients and clinicians in the negotiation of bilateral agreements could also help align the program with real‑world needs.

Patients await clarity.

For many living with diabetes, the cost of medication is a daily concern that can dictate health outcomes. If the public plan fails to incorporate the most effective therapies, patients may be forced into a compromise that could lead to complications, higher‑long‑term health costs, and reduced quality of life. The stakes are high, and the policy choices made now will shape the health system for years to come.

From a practical standpoint, a well‑designed pharmacare system would reduce the financial pressure on patients, allowing them to follow medical advice without worrying about affordability. It would also ease the administrative burden on clinicians who currently manage multiple insurance plans to secure the right drugs for their patients.

Advocates are urging the government to adopt a continuous improvement model, where the drug formulary is regularly reviewed and updated. This would prevent the program from becoming stagnant as medical science advances.

Stakeholders also stress the importance of equity. By focusing on uninsured and underinsured Canadians, the program could avoid leaving a segment of the population behind. A multi‑payer system, they argue, would better accommodate the different insurance systems across provinces and territories.

The next steps involve negotiations between the federal government and provincial and territorial authorities. These bilateral agreements will determine the final shape of the pharmacare program, including which medications are covered and how private plans will interact with the public system.

If the government succeeds in creating a flexible, inclusive framework, the national pharmacare program could become a model for other high‑cost, chronic conditions. Conversely, if the current design persists, the risk remains that many Canadians with diabetes will continue to face gaps in coverage, undermining the program’s stated goal of universal access.